Arax Advisory Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.3K | Sell |
703
-408
| -37% | -$3.66K | ﹤0.01% | 2151 |
|
|
2025
Q1 | $8.33K | Buy |
1,111
+373
| +51% | +$2.8K | ﹤0.01% | 1618 |
|
|
2024
Q4 | $5.55K | Hold |
738
| – | – | ﹤0.01% | 1706 |
|
|
2024
Q3 | $5.61K | Sell |
738
-40
| -5% | -$304 | ﹤0.01% | 1667 |
|
|
2024
Q2 | $4.81K | Buy |
778
+694
| +826% | +$4.29K | ﹤0.01% | 1614 |
|
|
2024
Q1 | $426 | Buy |
84
+32
| +62% | +$162 | ﹤0.01% | 1244 |
|
|
2023
Q4 | $312 | Hold |
52
| – | – | ﹤0.01% | 1255 |
|
|
2023
Q3 | $368 | Hold |
52
| – | – | ﹤0.01% | 1260 |
|
|
2023
Q2 | $367 | Buy |
52
+1
| +2% | +$7 | ﹤0.01% | 1225 |
|
|
2023
Q1 | $426 | Buy |
51
+13
| +34% | +$109 | ﹤0.01% | 1212 |
|
|
2022
Q4 | $436 | Buy |
+38
| New | +$436 | ﹤0.01% | 1194 |
|